## Shao-An Xue

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11800238/publications.pdf

Version: 2024-02-01

331670 361022 2,239 36 21 35 citations h-index g-index papers 36 36 36 2723 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. Journal of Clinical Investigation, 2008, 118, 3619-3628.	8.2	241
2	Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19078-19083.	7.1	183
3	Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. Journal of Hepatology, 2011, 55, 103-110.	3.7	183
4	Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene–transduced human T cells. Blood, 2005, 106, 3062-3067.	1.4	176
5	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. Journal of Hepatology, 2015, 62, 486-491.	3.7	160
6	Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 2005, 105, 3824-3832.	1.4	130
7	Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. Journal of Molecular Medicine, 2008, 86, 573-583.	3.9	108
8	Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. International Journal of Cancer, 2002, 99, 635-643.	5.1	101
9	CD3 limits the efficacy of TCR gene therapy in vivo. Blood, 2011, 118, 3528-3537.	1.4	101
10	Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood, 2011, 118, 319-329.	1.4	94
11	A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7934-7939.	7.1	87
12	Targeting the Wilms Tumor Antigen 1 by TCR Gene Transfer: TCR Variants Improve Tetramer Binding but Not the Function of Gene Modified Human T Cells. Journal of Immunology, 2007, 179, 5803-5810.	0.8	74
13	Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood, 2005, 106, 2936-2943.	1.4	58
14	Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica, 2010, 95, 126-134.	3 <b>.</b> 5	53
15	Monoclonal T-Cell Receptors: New Reagents for Cancer Therapy. Molecular Therapy, 2007, 15, 1744-1750.	8.2	50
16	WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells. Blood Cells, Molecules, and Diseases, 2008, 40, 113-116.	1.4	45
17	Human MHC Class I-restricted high avidity CD4 <sup>+</sup> T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncolmmunology, 2013, 2, e22590.	4.6	43
18	Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity. Cancer Research, 2014, 74, 5711-5722.	0.9	41

#	Article	IF	Citations
19	Effect of Vectors on Human Endothelial Cell Signal Transduction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 462-467.	2.4	38
20	Expression of Epstein-Barr virus lytically related genes in African Burkitt's lymphoma: Correlation with patient response to therapy. , 1999, 81, 6-11.		34
21	CD8α/α homodimers fail to function as co-receptor for a CD8-dependent TCR. European Journal of Immunology, 2007, 37, 1634-1641.	2.9	27
22	Expression of Two Related Viral Early Genes in Epstein-Barr Virus-Associated Tumors. Journal of Virology, 2000, 74, 2793-2803.	3.4	26
23	Genetic Diversity: Frameshift Mechanisms Alter Coding of a Gene (Epstein-Barr Virus LF3 Gene) That Contains Multiple 102-Base-Pair Direct Sequence Repeats. Molecular and Cellular Biology, 2003, 23, 2192-2201.	2.3	22
24	Complexities associated with expression of Epstein-Barr virus (EBV) lytic origins of DNA replication. Nucleic Acids Research, 2007, 35, 3391-3406.	14.5	21
25	T-cell receptor gene therapy for cancer: the progress to date and future objectives. Expert Opinion on Biological Therapy, 2007, 7, 1207-1218.	3.1	20
26	Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Molecular Therapy, 2018, 26, 2553-2566.	8.2	20
27	Emerging Strategies in TCR-Engineered T Cells. Frontiers in Immunology, 2022, 13, 850358.	4.8	20
28	CD8 T Cell Tolerance to a Tumor-Associated Self-Antigen Is Reversed by CD4 T Cells Engineered To Express the Same T Cell Receptor. Journal of Immunology, 2015, 194, 1080-1089.	0.8	19
29	Broadly expressed tumour?associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 1183-1192.	3.1	15
30	<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. Clinical Cancer Research, 2017, 23, 6178-6189.	7.0	11
31	Sensitivity of an Epstein-Barr Virus-Positive Tumor Line, Daudi, to Alpha Interferon Correlates with Expression of a GC-Rich Viral Transcript. Molecular and Cellular Biology, 1999, 19, 7305-7313.	2.3	8
32	African Burkitt's lymphoma: a new perspective. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 93-96.	1.8	7
33	Changing Viral Tropism Using Immunoliposomes Alters the Stability of Gene Expression: Implications for Viral Vector Design. Molecular Medicine, 2007, 13, 216-226.	4.4	7
34	Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy. Haematologica, 2016, 101, 482-490.	3.5	6
35	Burkitt's lymphoma: maximising the use of fine needle aspirates by long-term preservation for diagnosis and research. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, 105, 86-94.	1.8	5
36	A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 1367-1367.	1.4	5